Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Biogen
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02957617CT.gov Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 | — | Terminated | — | — | — |
NCT02935608CT.gov Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy | — | Completed | — | — | — |
NCT01561027CT.gov Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sciatica
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vixotrigine (this asset) | Biogen | P2 | B · 58 |
| Dexasone | University of Miami | P4 | BBB |
| Lidocaine | C.L.A.Vleggeert-Lankamp | P4 | BBB |
| Nepenthe | Akdeniz University | P4 | BB |
| Naproxen | Ostfold Hospital Trust | P4 | BB |
| (Rs)-Ketoprofen | University Hospital, Grenoble | P4 | BB |
| Prednisone | Kaiser Permanente | P3 | BB |
| Ibuprofen | St Joseph University, Beirut, Lebanon | P4 | BB |
| Kenacort | University of Miami | P4 | BB |
+36 more in the Sciatica cohort
Other indications for Vixotrigine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Trigeminal Neuralgia | — | P3 | B · 62 |
| Neuropathy, Painful | — | P1 | CC · 47 |
| Neuralgia | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vixotrigine in Sciatica. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vixotrigine-sciatica
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →